SAN DIEGO, CA--(Marketwired - Jul 19, 2016) - SpectraScience, Inc. (OTC PINK: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that they have signed a distribution agreement with Advanced Medical German Co. in Kuwait to be their exclusive distributor in the Middle East.
"We are pleased to be working with the premier distribution company for gastroenterology in the Middle East," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "We believe that with our innovative products and the sales, marketing, and distribution acumen of AMG in the Middle East we are poised to bring a new level of diagnostic capability to clinicians in colorectal cancer screening."
"Introducing innovative medical devices to our customers that improve patient outcomes is a hallmark of AMG. We believe the WavSTAT Optical Biopsy System has the potential to make screening for colorectal cancer less invasive and safer for patients, faster and more efficient for clinicians and, overall, less expensive for the health care system," said Dr. EYAD, President of AMG. "That combination of factors is attractive in any medical device market."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit the SpectraScience, Inc. website www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.